Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice | Journal of Investigative Medicine

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via AFMR

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via AFMR

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

Citation Tools

Original research

Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Carral San Laureano F, Tomé Fernández-Ladreda M, Jiménez Millán AI, et al

Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

Journal of Investigative Medicine Published Online First: 26 March 2021. doi: 10.1136/jim-2020-001633